Fluoxone

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fluoxone

What is Fluoxone? (Overview and Quick Facts)

Property Description
Active ingredient Fluoxetine Hydrochloride (Fluoxetine)
Form Capsules, Tablets, Oral Solution
Pharmacological class Selective Serotonin Reuptake Inhibitor (SSRI)
General purpose To help stabilize mood and emotional function
Origin Synthetic chemical compound

What Type of Medicine is Fluoxone (Fluoxetine)?

Fluoxone is a prescription medication whose active substance is Fluoxetine, chemically classified as Fluoxetine Hydrochloride. It is defined as an antidepressant belonging to the specific pharmacological class known as a Selective Serotonin Reuptake Inhibitor (SSRI). This classification identifies it as a synthetic molecule designed to modulate chemical signaling in the brain. The agent's mechanism is defined by its selective action on the neurotransmitter serotonin, which is thought to have a key influence on mood, emotion, and sleep. The primary, high-level general purpose of its use is to help stabilize mood and improve overall emotional well-being by addressing a hypothesized imbalance within the serotonin system.

Composition, Origin, and Available Forms

The core component of the medicine is the Fluoxetine molecule, a synthetic compound typically formulated as a salt to enhance stability and proper absorption following oral route administration. Fluoxetine is typically supplied as a single-agent product for systemic use. It is available in various oral route dosage form(s), including capsules, tablets, and an oral solution. The molecule is technically supplied as a racemic mixture, meaning it contains two molecular forms, with one form possessing the primary activity. This chemical structure is fundamental to its long duration of action in the body.

Regulatory References

  1. MedlinePlus Drug Information

What side effects are possible with Fluoxone?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety considerations for Fluoxone, strictly based on government regulatory documents.


Serious Safety Considerations

Black Box Warning: Government health authorities have issued a Boxed Warning regarding the increased risk of suicidal thinking and behavior in children, adolescents, and young adults (up to age 24) when starting treatment or when the dosage is changed. Patients in this age group require close monitoring.

Life-Threatening Events: Serious, potentially life-threatening adverse reactions include Serotonin Syndrome or Neuroleptic Malignant Syndrome (NMS)-like Reactions, which require immediate discontinuation and medical attention. There is also a documented risk of QT Prolongation (an electrical change in the heart) and associated ventricular arrhythmias, including Torsades de Pointes.

Contraindications and Restrictions

Fluoxone is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs) due to the risk of serious or fatal reactions. It is also contraindicated with the concurrent use of Pimozide and Thioridazine because of the risk of cardiac effects.

Population-Specific Risk: Caution is advised in elderly patients due to an increased risk of hyponatremia (low sodium levels). Use in late pregnancy may increase the risk of Persistent Pulmonary Hypertension of the Newborn (PPHN).


Common Adverse Reactions

The following are examples of adverse reactions reported as Very Common or Common in clinical trials:

Frequency Examples of Adverse Reactions (by System-Organ-Class)
Very Common Insomnia, headache, nausea, diarrhea, fatigue
Common Decreased appetite, anxiety, abnormal dreams, dry mouth, tremor, decreased libido, sweating, rash

Discontinuation of Fluoxone, particularly abrupt cessation, may result in withdrawal symptoms.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information emphasizes that any suspected overdose of Fluoxetine requires immediate, professional medical attention. There is no specific antidote known for Fluoxetine overdose; therefore, management is entirely supportive and focuses on addressing symptoms and complications as they arise in a hospital setting.

Documented Overdose Presentations

System Officially Documented Manifestations
Central Nervous System (CNS) Drowsiness, tremor, dizziness, confusion, seizures (which may be delayed), agitation, and coma.
Cardiovascular Tachycardia (fast heart rate), bradycardia, hypotension, and potentially delayed QTc interval prolongation and Ventricular Arrhythmia (including Torsades de Pointes).
Gastrointestinal Nausea and vomiting.

Life-Threatening Risks and Management

Severe, life-threatening outcomes reported with overdose include Serotonin Syndrome (especially with co-ingestion of other serotonergic agents) and serious cardiac events. Due to these risks, hospital management requires close observation and continuous Cardiac Monitoring (e.g., ECG) to monitor heart rhythm and electrical activity. Specific supportive measures, such as the administration of Activated Charcoal and symptomatic control (e.g., using benzodiazepines for agitation or seizures), are documented in official management protocols.

When Immediate Medical Help is Required

Seek emergency medical attention right away if an overdose is suspected. Immediately call emergency services (911) if the individual shows severe signs such as having a seizure, trouble breathing, or cannot be awakened (coma).

Therapeutic Uses of Fluoxone

What Fluoxone Treats: Main Uses and Benefits

Fluoxone (Fluoxetine) is generally used to provide supportive therapeutic benefit and ease the symptomatic burden across several core domains of mental health, helping patients cope more steadily with difficult episodes.

It is commonly used to help with conditions characterized by periods of heightened symptoms and emotional distress, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Bulimia Nervosa, and Premenstrual Dysphoric Disorder (PMDD). In clinical settings, Fluoxone is applied in addressing symptom clusters that may become intense or disruptive, such as persistent sadness, intrusive thoughts, compulsive behaviors, and acute panic episodes. It is relevant for easing symptoms that interfere with daily comfort when symptoms are more noticeable.


Quick Fact: Symptomatic support for Obsessive and Compulsive Manifestations Fluoxone is applied in addressing the disruptive thought-action cycle of OCD, assisting with managing both the frequency of obsessive thoughts and the intensity of associated ritualistic behaviors.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility Status

Fluoxone (Fluoxetine) is defined by regulatory agencies as being contraindicated (must not be used) for certain populations and requiring special caution or dose adjustment for others.

Absolute Non-Eligibility (Contraindications)

Population/Condition Status Regulatory Basis
Known hypersensitivity to Fluoxetine Contraindicated Must not be used
Concurrent use with an MAOI Contraindicated Strict 14-day/5-week washout required
Concurrent use with Pimozide or Thioridazine Contraindicated Risk of QT prolongation/drug interaction

Conditional Eligibility (Use with Caution)

Population/Condition Status Regulatory Basis
Hepatic Impairment Restricted Use Lower or less frequent dosage is recommended
History of Seizures Caution Required Must be used cautiously; monitor for seizure activation
Older Adults Special Consideration A lower or less frequent dosage should be considered

Age and Reproductive Status

  • Pediatric Use: The medication is established for use in children 8 years old for Major Depressive Disorder and 7 years old for Obsessive-Compulsive Disorder. Use in younger children is not established.
  • Pregnancy: Use is generally permitted only if the potential benefit outweighs the risk; third-trimester exposure may require monitoring.
  • Breastfeeding: Use is not recommended due to the passage of the drug and its active metabolite into breast milk.

What should I know about interactions with other medicines?

Fluoxetine can interact with other medicines and products, which may require dose adjustment or avoidance of the combination entirely.

Contraindicated Combinations

Fluoxetine must not be used concurrently with Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, as this combination significantly raises the risk of Serotonin Syndrome. A period of at least five weeks after stopping fluoxetine is required before starting an MAOI. Co-administration with the antipsychotics pimozide or thioridazine is also contraindicated due to the risk of abnormal heart rhythms (QTc prolongation).

Major Interaction Categories

Interacting Product Category Potential Risk/Mechanism
Serotonergic Agents (e.g., triptans, lithium, tramadol, buspirone, TCAs, St. John's Wort) Increased risk of Serotonin Syndrome due to additive effects.
Drugs Affecting Coagulation (e.g., NSAIDs, aspirin, warfarin) Increased risk of abnormal bleeding (hemorrhage) due to effects on platelet function.
CYP2D6 Substrates (e.g., certain antipsychotics, metoprolol, flecainide) Fluoxetine is a potent inhibitor of the CYP2D6 enzyme, which can lead to increased blood levels of these co-administered drugs and potential toxicity.
Other QTc-Prolonging Drugs Increased risk of heart rhythm abnormalities.

Caution is advised when combining fluoxetine with other centrally acting drugs, including certain anticonvulsants (like phenytoin and carbamazepine) and benzodiazepines, as their levels may be altered.

Mechanism of Action

Selective Serotonin Reuptake Control

Fluoxone's primary mechanism involves the selective inhibition of the Serotonin Transporter (SERT) protein in the brain. This action immediately prevents the neuron from recycling the neurotransmitter 5-HT (Serotonin), leading to a rapid and sustained increase in Serotonin concentrations in the synaptic space. This mechanism creates a new, elevated Serotonin signaling concentration within the CNS, which is the initial condition required for downstream adaptive changes.


Delayed Neural Adaptation and Remodeling

The establishment of the full physiological effect profile is constrained by time-dependent biological adaptation. Sustained 5-HT elevation triggers the desensitization and downregulation of inhibitory presynaptic autoreceptors ( 5-HT 1A) over several weeks, removing a biological feedback mechanism that temporarily limited 5-HT release. This chronic activity also promotes neuroplasticity (the capacity of neuronal connections to reorganize) via mechanisms involving BDNF signaling. This leads to long-term structural and functional changes in CNS circuits involved in affective processing.


Dual Action and Sustained Potency

Beyond its main target, Fluoxone also acts as an antagonist at the 5-HT 2C receptor, which contributes to the modulation of other monoamine systems. Furthermore, the parent drug is metabolized into Norfluoxetine, an active compound that retains potent SERT inhibitory activity. The metabolite's high affinity maintains the SERT inhibition mechanism for an extended period, supporting the conditions required for the long-term physiological adaptive changes to fully manifest.

Dosage and Administration Information

Fluoxone (Fluoxetine) is administered exclusively via the oral route and is officially supplied in several forms, including immediate-release capsules, tablets, and an oral solution. The standard practice involves taking the medicine once daily, typically in the morning, though daily doses exceeding 20 mg may be divided into morning and noon administration. Dosing is generally initiated at a low strength and may be gradually increased over several weeks according to the specific condition, but only up to the label-specified maximum dose.

The medicine may be taken with or without food as food intake does not significantly affect the absorption of the active ingredient. For Premenstrual Dysphoric Disorder (PMDD), a distinct pattern of intermittent use is officially approved, which involves taking the medicine only during the premenstrual phase of the cycle. The 90 mg delayed-release capsule is designed for a once-weekly schedule in maintenance treatment; patients switching to this weekly regimen must wait seven days after their last daily dose before initiating the first weekly dose.

Standard Adult Dosing Regimens (High-Level)

Indication Typical Maintenance Range Maximum Daily Dose
Major Depressive Disorder 20–40 mg once daily 80 mg
Obsessive-Compulsive Disorder 20–60 mg once daily 80 mg
Bulimia Nervosa Fixed dose: 60 mg once daily 60 mg

Usage protocols require population-specific adjustments. For both older adults and patients with hepatic impairment (liver cirrhosis), a lower or less frequent dose is generally utilized due to decreased clearance of the medicine and its active metabolites.

Recent Clinical Evidence

Research evidence / Overview of Studies for Fluoxone

This overview summarizes the structure and main findings of the official research evidence for Fluoxone, drawing primarily from randomized controlled trials (RCTs) and regulatory assessments. Research provides context but not individual predictions, and evidence highlights what is known — and what is still uncertain.


Evidence for Major Depressive Disorder (MDD)

Research exploring how symptoms change over time in Major Depressive Disorder (MDD) was primarily conducted using short-term, placebo-controlled clinical trials for the study of MDD in adults. These studies examined populations of adults and measured outcomes related to systemic or functional imbalance by using standardized rating scales to track changes in symptom intensity. Studies reported patterns where symptom measurements in the groups observed with Fluoxone often differed from those measured in groups receiving placebo.

Dedicated maintenance studies further examined the longer-term course of MDD. These studies were designed to monitor the frequency of symptom recurrence. Findings from these trials contribute to understanding symptom patterns over defined time intervals, particularly regarding symptom evolution during extended observation.


Evidence for Obsessive-Compulsive Disorder (OCD) and Bulimia Nervosa

Obsessive-Compulsive Disorder (OCD)

Fluoxone was studied in the context of Obsessive-Compulsive Disorder (OCD), a condition presenting with cycles of stability and flare-ups characterized by intrusive thoughts and ritualistic behaviors. The evidence is derived from short-term randomized controlled trials. Research examined outcomes reflecting daily functioning or activity level by measuring the change in the severity of obsessive thoughts and compulsive behaviors in both adults and pediatric patients. Studies report how symptoms evolved in the observed populations during the short treatment period.

Bulimia Nervosa

For Bulimia Nervosa, the evidence comes from acute treatment trials and a one-year maintenance study. Research explored short-term symptom changes by monitoring the frequency of key behavioral outcomes, specifically binge-eating episodes and purging activities in adult outpatients. The available maintenance study reported on patterns of relapse and symptom return.


Research Gaps and Areas of Uncertainty

Evidence is limited regarding the durability of responses over many years for most of the approved indications. Comparative evidence is lacking for certain groups, meaning there are fewer studies directly comparing Fluoxone against other available interventions. Additionally, specific subgroup findings are uncertain; for instance, understanding the effects on children’s physical development was noted as an area for careful monitoring and further research in the regulatory record.

Frequently Asked Questions (FAQ)

Common questions about Fluoxone (FAQ)


Q: How quickly should I expect to feel a difference after starting Fluoxone?

Studies and official information indicate that the full effect of Fluoxone may be subject to a delay. For conditions like Major Depressive Disorder, it is noted that the full response may not be seen until four weeks of treatment or even longer as the body adjusts to the medicine.


Q: How long does Fluoxone typically stay in your system?

The active ingredient in Fluoxone, and its main active metabolite, both have long half-lives. This means they are eliminated from the body slowly and can take several weeks to be substantially cleared from the system. Due to this characteristic, the medicine accumulates in the body with regular use until it reaches a steady concentration.


Q: Can you take Fluoxone while pregnant or breastfeeding?

Official documentation states that use during pregnancy is considered only when the potential benefit is determined to outweigh the possible risk; monitoring may be required with exposure during the third trimester. Use while breastfeeding is not recommended, according to official information, because the medicine and its active metabolite pass into breast milk.


Q: Why does Fluoxone sometimes take several weeks to start working?

The full effect of Fluoxone relies on a process called time-dependent biological adaptation within the central nervous system. This process involves a necessary period of adjustment. The adaptation is what creates the conditions necessary for the full therapeutic benefit to manifest, and it typically takes several weeks.


Q: What evidence exists about Fluoxone's effectiveness in older adults?

Official usage protocols state that a lower or less frequent dose is generally utilized for older adults due to potential decreased clearance of the medicine. Additionally, regulatory overviews indicate that comparative evidence—meaning studies that directly compare Fluoxone against other available interventions—may be limited for this specific population.


Q: Do the official reports describe Fluoxone as a short-term or long-term treatment?

Official reports describe the medicine's use in the context of both short-term and long-term treatment. Regulatory documents reference acute studies designed to measure short-term symptom change and dedicated maintenance studies designed to monitor symptom patterns over extended time intervals, depending on the approved use.


Q: Does Fluoxone cause weight gain?

Official documentation notes that altered appetite and weight effects have been observed during treatment with Fluoxone. Specifically, clinical trial data has observed that significant weight loss has occurred in some study participants.


Q: Can Fluoxone be taken with common over-the-counter pain relievers?

Official documents indicate that caution is advised when Fluoxone is used concurrently with certain nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and aspirin. This is due to a potentially increased risk of abnormal bleeding when the medicines are taken together.


Q: Is it normal to feel a change in sleep patterns when starting Fluoxone?

Changes to sleep patterns are commonly documented as adverse reactions associated with the medicine. This can include insomnia (difficulty sleeping) or abnormal dreams. Other related effects like fatigue and somnolence (sleepiness) are also listed and may be noticeable during the initial adjustment period.


Q: Is it necessary to have routine blood work while taking Fluoxone?

Official documents do not mandate general routine blood work for all patients. However, they indicate the potential need for monitoring specific conditions. For example, blood levels of co-administered medicines (like Tricyclic Antidepressants) may need monitoring, and special consideration is noted to monitor for conditions such as low sodium levels (hyponatremia), particularly in older adults.


Q: Does taking Fluoxone change your appetite?

Clinical documentation lists a change in appetite as a common adverse reaction. Specifically, decreased appetite (also referred to as anorexia) is listed in the official documents.


Q: Is Fluoxone addictive or habit-forming?

The core documents do not use the terms 'addictive' or 'habit-forming' to describe the medication. However, official information does state that abrupt discontinuation of the medicine may result in withdrawal symptoms, indicating that the body requires time to adjust when stopping treatment.


Q: Is Fluoxone known to cause dizziness or confusion?

According to official clinical trial documentation, dizziness and somnolence (sleepiness) are listed as common adverse reactions. These effects are reported during the course of treatment.


Q: Can Fluoxone affect mental clarity or focus?

Official labeling warns that side effects may include potential effects on cognitive function. This includes reports of impaired judgment and attention deficits. Due to these potential effects, caution is advised for activities requiring sharp focus.


Q: Is Fluoxone available in different strengths?

Fluoxone is supplied in various oral dosage forms. Official product information lists immediate-release capsules and tablets in multiple strengths, such as 10 mg, 20 mg, and 40 mg.


Q: Does Fluoxone interact with common supplements like St. John's Wort or melatonin?

Official documents caution that the herbal supplement St. John's Wort is classified as a serotonergic agent. Combining this supplement with Fluoxone increases the risk of Serotonin Syndrome due to the additive effects on the serotonin system.


Q: Do users report feeling tired when they first start Fluoxone?

Fatigue (asthenia) and somnolence (sleepiness) are officially listed as common adverse reactions of Fluoxone. These effects are often reported during the initial phase of treatment as the body begins to adjust to the medication.


Q: Can Fluoxone be crushed or split if the pill is too large?

Official instructions for the tablet and capsule forms state that the medication should be taken by mouth with water. The instructions explicitly direct that the medication should not be cut, crushed, or chewed.


Q: What are the recommended lab tests mentioned in the official documents for Fluoxone?

Official documents indicate the potential need to monitor concentrations of co-administered medicines, such as Tricyclic Antidepressants (TCAs). They also advise monitoring for conditions such as hyponatremia (low sodium levels), especially in certain populations.


Q: Are there restrictions on driving or operating machinery while on Fluoxone?

The official labeling warns that the medication may impair the ability to perform tasks requiring psychomotor or cognitive function. This warning is provided because the effects could interfere with activities such as driving or operating machinery.


Q: What makes Fluoxone different from an SSRI?

Fluoxone is not different from an SSRI; it belongs to this class of medication. Regulatory agencies classify Fluoxone as an antidepressant and specifically categorize it as a Selective Serotonin Reuptake Inhibitor (SSRI).


Q: Is it safe to switch from another medication to Fluoxone?

Official documents provide specific instructions for switching from certain other medicines, such as noting the need for a five-week washout period after stopping a Monoamine Oxidase Inhibitor (MAOI) before beginning Fluoxone.


Q: Is Fluoxone associated with vision changes?

Clinical trial data has noted potential ocular effects associated with the use of this medication. These effects include the occurrence of blurred vision and dry eye.

How should Fluoxone be stored and disposed of?

How to Store and Dispose of Fluoxetine (Fluoxone)

Fluoxetine must be stored under specific, officially documented environmental conditions to maintain its quality and efficacy.

Storage and Protection

Requirement Details
Temperature Store at controlled room temperature, typically 20 °C to 25 °C (68 °F to 77 °F). Do not store above 25 °C.
Protection Keep the container tightly closed and away from both light and excessive moisture.
Child Safety The medication must be kept out of the reach and sight of children.

Disposal Instructions

Unused or expired fluoxetine should be discarded using a drug take-back program if one is available. Fluoxetine is not on the list of medicines recommended for flushing down the toilet. If a take-back option is unavailable, the medication should be mixed with an undesirable substance, such as dirt or used coffee grounds, placed in a sealed bag or container, and then thrown into the household trash. Disposal must adhere to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Fluoxone found in:

A-Z Index: